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Abstract 
This study examines the relationship of genotype to phenotype in 14 unselected patients who were found to harbour the A3243G 
transition in the mitochondrial transfer RNA Leu(UtJ~) gene commonly associated with the syndrome of mitochondrial encephalopathy, 
lactic acidosis and strokes (MELAS). Only 6 of the 14 cases (43%) had seizures and recurrent strokes, the core clinical features of the 
MELAS phenotype. Of the remaining cases, four had an encephalomyopathy with deafness, ataxia nd dementia, two had syndromes with 
progressive external ophthalmoplegia and two had limb weakness alone. Even within the MELAS subgroup, the majority of patients had 
one or more clinical manifestations considered to be atypical of the MELAS syndrome. They included developmental delay, 
ophthalmoparesis, pigmentary retinopathy and intestinal pseudo-obstruction. The proportion of mutant mitochondrial DNA (mtDNA) in 
muscle was generally higher in patients with recurrent strokes than in those without strokes, the highest levels being observed in MELAS 
cases with early onset disease. Studies of isolated muscle mitochondria identified a range of respiratory chain abnormalities mostly 
involving Complex I; immunoblots of Complex I in 3 of 10 cases showed selective loss of specific subunits encoded by nuclear genes. In 
the group as a whole, however, no clear correlations were observed between the severity or extent of the respiratory chain abnormality 
and clinical phenotype or the proportion of mutant mtDNA in biopsied skeletal muscle. These discrepancies suggest hat, in patients 
harbouring the common MELAS 3243 mutation, differences in heteroplasmy and the proportions of mutant mtDNA may not be the sole 
determinants of disease xpression and that additional genetic mechanisms are involved in defining the range of clinical and biochemical 
phenotypes associated with this aberrant mitochondrial genome. 
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I. Introduction 
Despite the recent discovery of mitochondrial DNA 
(mtDNA) mutations in an increasing number of mitochon- 
drial myopathies and encephalomyopathies [1,2], the 
mechanisms which account for the complex relationship 
between mtDNA genotype and clinical phenotype have not 
been resolved [3,4]. The association of different syndromes 
with the same mutation [5-11] and different mutations 
with the same syndrome [12-15] has not only made it 
difficult to classify these diseases on the basis of mtDNA 
analysis alone [4,16] but has prompted speculation that 
additional mechanisms uch as the genetic background 
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[3,16-18], immunological [ 19-21 ] or environmental fac- 
tors [22,23] and even the ageing process itself [24,25] may 
be important contributory determinants of clinical pheno- 
typic expression. 
The range of disorders associated with these single gene 
defects is exemplified by the MELAS mutation, an A3243G 
transition in the mitochondrial tRNA I~eu(tJU~) gene [26]. 
This single base change in a mitochondrial gene involved 
in transcriptional control as well as RNA processing and 
translation [27] accounts for 80% of all patients with 
MELAS (mitochondrial encephalomyopathy, lactic acido- 
sis and strokes) [26,28-30] but it also occurs in other 
syndromes in which progressive xternal ophthalmoplegia 
(PEO) [6,7,26], diabetes mellitus and deafness [8,31] or 
limb weakness with exercise intolerance [6,7] are the cardi- 
nal clinical manifestations. The converse also applies in 
that each of the above syndromes, including MELAS, has 
been linked to more than one mtDNA genotype [14,32-34]. 
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We have examined the clinical and biochemical pheno- 
types in 14 patients harbouring the A3243G mutation in 
the mitochondrial tRNA eeu(UuR) gene, 6 of whom had the 
MELAS syndrome. The results are discussed in relation to 
the polypeptide profiles of Complex I and Complex IV and 
the relative proportions of mutant mtDNA identified in 
biopsied samples of skeletal muscle. 
2. Materials and methods 
Mitochondria were freshly isolated from biopsied sam- 
ples of the vastus lateralis muscle taken under light general 
anaesthesia [34]. Polarographic studies, low temperature 
(77K) measurements of the mitochondrial cytochromes 
and assays of the respiratory chain enzymes were carried 
out using standard techniques [34]. Immunoblots of Com- 
plex I and Complex IV were performed using polyclonal 
antibodies to the bovine holoenzymes and subunit specific 
antisera to 6 Complex I subunits (75, 51, 49, 30, 24, 13 
kDa) and subunits II and IV of Complex IV [19,35]. DNA 
was extracted from blood and/or muscle [34,36] and 
digested with ApaI [6]. Fragments were separated on a 
1.6% agarose gel, Southern blotted and hybridised to a 
polymerase chain reaction (PCR) product corresponding to
mtDNA nucleotides 3054-5481. The proportion of mutant 
mtDNA was estimated using a Phosphor Imager (Molecu- 
lar Dynamics). All investigations were undertaken with the 
informed consent of the patient and approval of the local 
Ethics Committee. 
3. Clinical phenotypes 
Four clinical syndromes were identified (Table 1, A-D). 
Six patients (43%) from five pedigrees had the core clini- 
cal features of seizures, intellectual decline and recurrent 
strokes consistent with the MELAS phenotype [26,28,29]. 
Age of onset ranged from birth to early adult life. Focal or 
generalised seizures or drop attacks were initial symptoms 
in four cases. 
One patient, who was hypotonic at birth, had delayed 
motor milestones and a scoliosis treated with a spinal 
brace. He suffered occasional migrainous-type h adaches 
in the first decade, seizures and recurrent strokes in his 
mid teens and died of cardiorespiratory failure at the age 
of 24 years. Another patient presented with symptoms of 
intestinal dysmotility and subsequently developed pseudo- 
obstruction requiring surgery. Her illness ran a rapidly 
progressive course leading to death at the age of 24 years. 
Another patient developed intestinal pseudo-obstruction as 
a pre-terminal event. Although stroke-like pisodes are the 
main hallmark of MELAS, they occurred as an early 
feature of the disease in only two cases. In four cases, 
strokes only became vident between 7 and 15 years after 
the onset of the disease. Pigmentary retinopathy occurred 
in four cases and was associated with sensorineural deaf- 
ness in three, mild ophthalmoparesis in two and an axonal 
neuropathy in one. Short stature was noted in two cases. 
Except for the mother and son, none of the patients in 
Group A had definitely affected relatives. The mother of 
Case 73, however, had occasional seizures in the past and 
Table 1 
A3243G tRNA L~U(uUR) mutation: clinical features in 14 cases 
Case/ Age at onset Age at F.H. Evolution of symptoms (additional features on examination) 
sex (death) investigation 
(A) Cases with recurrent strokes 
21a/F 20's (47) 42 
21b/M 6(18) 12 
73/M Childhood (18) 15 
75/M Birth (24) 23 
86/F 15 (24) 23 
119/F Infancy 19 
+ ve Drop attacks, ataxia, cardiac failure, seizures, strokes, dementia, pseudo-obstruction 
(ophthalmoparesis, pigmentary retinopathy, deafness) 
+ ve Seizures, intellectual decline, ataxia, deafness, trokes, myoclonus, coma (pigmentary etinopathy) 
? Seizures, intellectual decline, strokes, ataxia, deafness (optic atrophy, short stature) 
- ve Hypotonic at birth, delayed milestones, coliosis, headaches, seizures, strokes, dementia, taxia, 
cardiomyopathy, cardiorespiratory failure (ophthalmoparesis, p gmentary retinopathy, deafness) 
- ve Intestinal pseudo-obstruction, seizures, strokes, ataxia, dementia 
(axonal neuropathy, pigmentary etinopathy) 
- ve Seizures, delayed milestones, intellectual decline, strokes, severe dementia (short stature) 
(B) Cases with deafness, ataxia and dementia (without strokes) 
20/M 20's (61) 58 - ve Diabetes, deafness, ataxia, dementia (axonal neuropathy) 
76/M 30 35 + ve Deafness, ataxia, dementia, diabetes (pigmentary etinopathy) 
77/F Teens 52 + ve Deafness, myoclonus, ataxia, dementia (pigmentary etinopathy) 
79/M 30's 40 - ve Deafness, diabetes, cardiomyopathy, ataxia, dementia, renal failure (pigmentary etinopathy) 
(C) Cases with progressive external ophthalmoplegia (PEO) 
39/M Teens 42 - ve PEO, limb weakness, exercise intolerance, single stroke at 47 years, diabetes 
113/F 40's 58 - ve PEO, deafness, limb weakness (pigmentary etinopathy, axonal neuropathy) 
(D) Cases with limb weakness and exercise intolerance 
21c/F 12 21 + ve Limb weakness and fatigue 
74/F 8 51 + ve Ptosis, limb weakness, exercise intolerance 
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was said to have ragged red fibres in biopsied muscle. The 
mother of case 119 harboured a small percentage of mu- 
tant mtDNA in biopsied muscle but was asymptomatic. 
Adult onset deafness, ataxia and dementia were the core 
clinical features in four cases (Table IB). Diabetes and/or 
deafness were initial symptoms in all four cases but one 
patient had occasional myoclonic jerks. Pigmentary 
retinopathy occurred in three patients, one of whom devel- 
oped cardiomyopathy and chronic renal disease unrelated 
to his diabetes. Two patients in this group had affected 
relatives. Case 77 was the proband of a large Norwegian 
pedigree with a maternally inherited mitochondrial en- 
cephalomyopathy recently described by Torbergsen et al. 
[37] and the older brother of Case 76 died from an 
undiagnosed progressive encephalopathy in the third 
decade. Case 20 died suddenly aged 61 years from a 
suspected myocardial infarct. The remaining three cases in 
Group B are alive and have not developed strokes over a 
follow-up period exceeding 10 years. 
PEO with variable limb weakness were the presenting 
features in two cases (Table 1C). One patient (Case 113) 
had deafness, pigmentary retinopathy and an axonal neu- 
ropathy and the other (Case 39) suffered a single stroke 
aged 47 years which resolved and has not recurred. This 
patient, now aged 53 years, has recently developed ia- 
betes controlled with oral hypoglycaemic agents. His 
mother was said to have been weak in later life. 
Limb weakness with exercise intolerance occurred in 
two cases (Table 1D). Case 21c, the daughter of Case 21a, 
developed easy fatigueability in her early teens which has 
not progressed. The second patient (Case 74) first noticed 
weakness and exercise intolerance in childhood. She is 
now in her early 60's and has not developed new symp- 
toms. Her sister died in the third decade with facioscapulo- 
humeral weakness and her brother, who had PEO, died in 
coma in the sixth decade. 
4. mtDNA genotype 
Except for Case 21 a, the proportion of mutant mtDNA 
in muscle was generally higher in patients with stroke-like 
episodes than in those without strokes (Table 2). Within 
the MELAS subgroup, the proportion of mutant mtDNA 
was related to age of onset of the disease. The highest 
levels of mutant mtDNA occurred in the two patients with 
onset in infancy (Cases 75, 119) and the lowest level was 
identified in Case 21a with adult onset disease. Average 
values for the proportions of mutant mtDNA in muscle 
were 81% for MELAS cases (Group A), 77% for patients 
with deafness, ataxia and dementia (Group B) and 59% for 
patients with PEO (Group C). 
5. Biochemical phenotypes 
On the basis of the polarographic studies, the defect 
was localised to Complex I in seven cases (Table 2). They 
included three patients with MELAS (Cases 21a, 73, 75), 
two with the syndrome of deafness, ataxia and dementia 
(Cases 76, 77) and the two patients with myopathy alone 
(Cases 21c, 74). The mitochondrial cytochromes were 
normal in one patient (Case 75) but the aa 3 content was 
below the control range in six (Cases 21a, 21c, 73, 74, 76, 
77) and, in one case (73), cytochrome b was also reduced. 
In four patients, one with MELAS (Case 119), one with 
Table 2 
A3243G tRNA l~u(tJUR) mutation: biochemical features, polypeptide profiles and percentages of mutant mtDNA in 14 cases 
Case Defects Polypeptide profiles 
Complex I Complex IV 
% Mutant mtDNA 
in muscle 
(A) 
21a Complex I$ aa 3 $ Generalised reduction 
21 b Normal Normal 
73 Complex I $ b $ aa 3 $ Generalised reduction 24 kDa 
75 Complex I $ Generalised reduction 13 kDa$ 
86 aa 3 ~, ND 
119 Complex I-III+ aa 3 ,1, ND 
(B) 
20 Complex I-III $ b $ aa 3 $ Generalised reduction 
76 Complex I $ aa 3 $ Generalised reduction 
77 Complex I $ aa 3 $ Generalised reduction 
79 aa~ $ Normal 
(c) 
39 Complex I-III J, Normal 
113 Complex I-III J, aa 3 ,1, ND 
(D) 
21c Complex I+ aa 3 ,1, ND 
74 Complex I ,L aa3,1, Generalised reduction 24 kDa & 13 kDa ,1, 
a Percentage in blood. 
ND: not done. 
Normal 54 
ND 80 
Cox II $ 80 
Normal 91 
ND 86 
ND 95 
Normal 77 
ND 77 
Normal 77 
Normal 78 
ND 75 
ND 44 
ND 53 
Cox It ~, 91 a 
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Table 3 
Defect No of cases%3243 
Complex I 1 (7591 )
Complex I+aa 3 5 (21a 54, 7677, 7777, 21c 53, 7491 a) 
Complex I + aa 3 + b 1 (738°) 
Complex I-III 1 (3975) 
Complex I-III + aa 3 2 (11344, 11995) 
Complex I-III + aa 3 + b 1 (2077) 
aa 3 2 (8686, 7978) 
No defect 1 (21b 8°) 
Percent in blood. 
Complex I and a reduced concentration of aa 3, showed 
selective loss of the 24 kDa and 13 kDa polypeptides of 
Complex I and subunit II of Complex IV (Table 2). 
Immunoblots of Complex IV in five cases were normal. 
They included three patients with a generalised reduction 
of Complex I subunits, one patient with selective defi- 
ciency of the 13 kDa polypeptide and one patient with a 
reduced level of cytochrome aa 3. 
7. Discussion 
deafness, ataxia and dementia (Case 20) and both patients 
with PEO (Cases 39, 113), the polarographic defect in- 
volved Complexes I - I I I  and was associated with reduced 
aa 3 in two cases (119, 113) and reduced aa 3 and b in one 
(Case 20). Polarographic studies were normal in three 
cases (21b, 79, 86) but, in cases 79 and 86, aa 3 levels 
were reduced to 56% and 48%, respectively, of the mean 
control value. Although the lowest oxygen uptake rates 
utilising pyruvate or succinate were recorded in Case 119, 
who had the highest proportion of mutant mtDNA, in the 
remaining 13 cases no clear correlations were observed 
between the severity of the respiratory chain defect and 
clinical phenotype or the relative proportion of mutant 
mtDNA in skeletal muscle. Polarographic studies were 
normal in two MELAS cases with 80 and 86% mutant 
mtDNA, respectively, (Cases 21b, 86) whereas in Case 73 
with 80% mutant mtDNA, the oxygen uptake rate utilising 
pyruvate and the aa 3 content were reduced to 20% and 
22%, respectively, of the mean control values. Moreover, 
in Case 113, with the lowest level of mutant mtDNA in 
muscle, respiratory rates with pyruvate and succinate were 
32% and 55%, respectively, of the control means. The 
range of biochemical abnormalities and the percentages of
mutant mtDNA identified in skeletal muscle from the 14 
cases are summarised in Table 3. 
6. Respiratory chain polypeptides 
Immunoblots of Complex I were normal in three of the 
ten cases studied (Table 2). Polarographic studies were 
normal in two of these cases (21b, 79) but the third patient 
(Case 39) showed a defect in Complexes I - I I I  with normal 
cytochromes. In four patients (Cases 20, 21a, 76, 77), there 
was a generalised and proportional reduction in all cross- 
reacting bands which paralleled the decrease in Complex I
activity as determined polarographically. In addition to a 
generalised reduction of immunoreactive polypeptides, two 
patients with MELAS (73, 75) showed selective loss of a 
specific Complex I subunit which was identified as the 24 
kDa polypeptide in Case 73 and the 13 kDa polypeptide in 
Case 75 using subunit specific antisera. Case 73 also 
showed selective loss of subunit II in Complex IV. Case 
74 with myopathy only, who had a severe defect in 
This study illustrates the diverse clinical and biochemi- 
cal features in 14 unselected patients with evidence of 
mitochondrial dysfunction who were found to harbour the 
A3243G transition in the mitochondrial tRNA L~u(UUR/gene. 
Despite a high level of concordance between the MELAS 
syndrome and the common MELAS 3243 mutation [26,28- 
30], the majority of these patients did not have the MELAS 
phenotype. Even within the MELAS sub-group, most pa- 
tients had one or more clinical features which were not 
typical of the MELAS syndrome as originally defined [38]. 
Intestinal dysmotility with pseudo-obstruction, which oc- 
curred in two MELAS cases, is one of the four cardinal 
features of another mitochondrial multisystem disease, best 
known by the acronym MNGIE (mitochondrial neurogas- 
trointestinal encephalomyopathy) [40]. This syndrome, re- 
cently associated with multiple mtDNA deletions, is 
thought o be inherited as a recessive mendelian trait [41]. 
Pigmentary. retinopathy, another atypical manifestation of 
MELAS [29,30,39] but an invariant feature of the Kearns 
Sayre syndrome [42] usually associated with large-scale 
single deletions of mtDNA [4,34,43], occurred in more 
than half of the cases overall and was present in 4 of 6 
patients with MELAS. Moreover ecurrent strokes, perhaps 
the sole exclusive clinical manifestation of the MELAS 
syndrome, were a late feature of the disease in the majority 
of cases. Diabetes mellitus, another manifestation recently 
associated with the MELAS 3243 mutation [8,31] was sur- 
prisingly lacking in the MELAS sub-group, but occurred in 
3 of 4 patients with the syndrome of deafness, ataxia and 
dementia nd one of two patients with PEO who suffered a
single stroke. 
In keeping with previous tudies [29], the proportion of 
mutant mtDNA was mostly higher in patients with recur- 
rent strokes than in those without strokes. Within the 
MELAS sub-group, the highest levels occurred in patients 
with early onset disease. Case 119, however, who had the 
highest percentage of mutant mtDNA in muscle is the only 
surviving member of the MELAS sub-group. Now aged 33 
years, she is severely demented but remains fully ambulant 
and has not had a seizure or a clinically evident stroke for 
several years. In contrast, case 39 with a significantly 
lower percentage of mutant mtDNA in muscle has dis- 
abling weakness and exercise intolerance and requires a 
stick to walk. 
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The mechanisms of the A3243G transition in disease 
pathogenesis remain unclear. In addition to possibly alter- 
ing the stability and function of one of the two leucyl-tRNA 
species, the mutation is located within a 13 nucleotide 
template which binds the transcription termination factor 
mTERF [44,45]. Although the binding of mTERF to the 
MELAS template is greatly reduced in vitro [44,46] quali- 
tative alterations in transcription termination (or RNA 
processing) do not appear to account for the greatly de- 
creased rates of synthesis and steady-state levels of mtDNA 
encoded proteins observed in biopsied muscle fibres and 
cell culture systems containing above threshold levels (> 
90%) of the mutation, [46-49]. 
The mtDNA encoded polypeptides with the highest 
proportion of leucine (UUR) residues are the complex 1 
subunits ND6 and ND3. Although the precise functions of 
these subunits are not known, loss of ND6 or ND3 (or 
both) may explain why complex 1 deficiency is the most 
common respiratory chain defect observed polarographi- 
cally in these and other patients with the MELAS 3243 
mutation [30]. Quantitative alterations in transcriptional 
control [50] or translational efficiency [51] could also 
account for the decreased levels of aa 3 and/or b or the 
more extensive reduction in respiratory chain activity which 
were observed in 10 of the present cases. However, it is 
more difficult to envisage how these genetic mechanisms 
could account for selective loss of one or more specific 
complex 1 subunits encoded by nuclear genes. It is possi- 
ble that, in the presence of impaired assembly of the 
complex resulting from reduced synthesis of mtDNA en- 
coded subunits, certain nuclear encoded complex 1 poly- 
peptides, by virtue of their structure or position within the 
holoenzyme, may be more susceptible to proteolytic degra- 
dation. Lack of assembly of mtDNA encoded subunits of 
complex 1 with complete loss of NADH-CoQI oxido- 
reductase activity has been identified in a human cell line 
with a frame-shift mutation in the ND4 gene but nuclear 
encoded complex 1 polypeptides were not studied [52]. 
Although such a mechanism cannot be excluded in the 
present cases, it would seem unlikely as loss of specific 
nuclear encoded subunits was not observed in other pa- 
tients with equally severe reductions in complex 1 activity 
and in immunoreactive complex 1 subunits. 
The range of clinical (and biochemical) phenotypes 
associated with the A3243G transition and with other 
pathogenic mtDNA mutations which eliminate (deletions) 
or alter (point mutations) tRNA genes [4,15] is often 
considered to depend ultimately on variations in the degree 
of mtDNA heteroplasmy in the different issues and on the 
threshold levels of mutant mtDNA required to cause cellu- 
lar and organ dysfunction [1,3,25]. In studies of cell culture 
systems harbouring the MELAS 3243 mutation, as little as 
10% wild-type mtDNA is sufficient o prevent expression 
of the mutant phenotype [46,48]. This protective ffect 
appears to be due to translational complementation [53,54], 
possibly mediated by mitochondrial fusion [55]. Limited 
autopsy studies, however, have questioned the importance 
of the so-called threshold effect in disease pathogenesis a
universally high levels of mutant mtDNA have been identi- 
fied, even in organs which function normally during life 
and shown no biochemical or histological abnormality 
[56,57]. Such discrepancies may reflect differences in 
mtDNA transcription [58] and/or translational efficiency 
[51]. 
The degree of mtDNA heteroplasmy in an individual 
harbouring one of these pathogenic mutations is thought o 
be determined by the dose of mutant mtDNA in the 
fertilised ovum and the way in which mutated and wild-type 
genomes are segregated and replicate during development. 
Mitotic segregation is thought o be random, but mtDNA 
replication and expression are controlled by nuclear genes. 
Studies of mtDNA heteroplasmy in the male marine mus- 
sel suggest hat factors involved in the replication and the 
partitioning of mitochondrial genomes may be selective for 
a specific population of mtDNA [59]. Moreover, disease 
associated deletions and possibly point mutations in 
mtDNA appear to accumulate with age [60-62] but within 
the life-span of a normal individual they do not reach the 
threshold levels required for mtDNA disease expression. 
The role of nuclear genes in determining mtDNA genotype 
and both clinical and biochemical phenotype in the mtDNA 
associated iseases requires further study. 
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